This study is looking at a new way to treat diffuse large B-cell lymphoma (DLBCL), a type of cancer that starts in white blood cells. It combines standard chemotherapy (like R-CHOP or similar treatments) with a special approach using low-dose radiation therapy (LDRT). After two cycles of chemotherapy, doctors will check your blood for minimal residual disease (MRD), which means a very small amount of cancer cells that might still be present, and also use PET imaging to see if any cancer remains. If MRD is found, you might receive low-dose radiation to those areas. If no MRD is found, you'll continue with standard chemotherapy. The main goal is to see if this approach is practical and safe. You can join if you are an adult aged 19 or older with newly diagnosed DLBCL and are planning to receive 6 cycles of standard chemotherapy.

Study design

This is a single-arm study, meaning all participants receive the same general treatment approach. It aims to enroll 50 participants and is evaluating a new treatment strategy.

What's involved

You would receive standard chemotherapy and have blood tests and PET scans after two cycles of treatment. If needed, you might also receive low-dose radiation therapy.

Compensation

Not stated in the trial record.

Follow-up

The feasibility of the treatment strategy will be measured from the start of treatment through its completion, which is approximately 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.